Lipocine
LPCN
19 hedge funds and large institutions have $29.7M invested in Lipocine in 2015 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 8 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
59% more capital invested
Capital invested by funds: $18.7M → $29.7M (+$11.1M)
14% less funds holding
Funds holding: 22 → 19 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.26M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$576K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$512K |
| 4 |
Renaissance Technologies
New York
|
+$159K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$136K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$652K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$71K |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$69.3K |
| 4 |
Morgan Stanley
New York
|
-$28K |
| 5 |
Citigroup
New York
|
-$26K |
LPCN Hedge Fund Activity: Q1 2015 in Review
19 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2015, worth a combined $29.7M — up 59% from $18.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LPCN and 5 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $4.26M. The largest seller was Millennium Management, exiting entirely with an estimated $652K sold.
- 19 institutional investors held Lipocine (LPCN) as of Q1 2015, down from 22 in Q4 2014.
- Funds reported $29.7M of Lipocine stock for Q1 2015, up 59% quarter-over-quarter.
- 5 funds opened new Lipocine positions in Q1 2015 and 8 closed out, a net change of -3 holders.
- The largest Lipocine buyer in Q1 2015 was Cormorant Asset Management, an estimated $4.26M added.
- The largest Lipocine seller in Q1 2015 was Millennium Management, an estimated $652K sold.
Based on aggregated 13F filings for Q1 2015.